Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 536

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Open access
Kyriazopoulou, Evdoxia, Poulakou, Garyfallia, Milionis, Haralampos, Metallidis, Simeon, Adamis, Georgios, Tsiakos, Konstantinos, Fragkou, Archontoula, Rapti, Aggeliki, Damoulari, Christina, Fantoni, Massimo, Kalomenidis, Ioannis, Chrysos, Georgios, Angheben, Andrea, Kainis, Ilias, Alexiou, Zoi, Castelli, Francesco, Serino, Francesco Saverio, Tsilika, Maria, Bakakos, Petros, Nicastri, Emanuele, Tzavara, Vassiliki, Kostis, Evangelos, Dagna, Lorenzo, Koufargyris, Panagiotis, Dimakou, Katerina, Savvanis, Spyridon, Tzatzagou, Glykeria, Chini, Maria, Cavalli, Giulio, Bassetti, Matteo, Katrini, Konstantina, Kotsis, Vasileios, Tsoukalas, George, Selmi, Carlo, Bliziotis, Ioannis, Samarkos, Michael, Doumas, Michael, Ktena, Sofia, Masgala, Aikaterini, Papanikolaou, Ilias, Kosmidou, Maria, Myrodia, Dimitra-Melia, Argyraki, Aikaterini, Cardellino, Chiara Simona, Koliakou, Katerina, Katsigianni, Eleni-Ioanna, Rapti, Vassiliki, Giannitsioti, Efthymia, Cingolani, Antonella, Micha, Styliani, Akinosoglou, Karolina, Liatsis-Douvitsas, Orestis, Symbardi, Styliani, Gatselis, Nikolaos, Mouktaroudi, Maria, Ippolito, Giuseppe, Florou, Eleni, Kotsaki, Antigone, Netea, Mihai G., Eugen-Olsen, Jesper, Kyprianou, Miltiades, Panagopoulos, Periklis, Dalekos, George N., Giamarellos-Bourboulis, Evangelos J.·2021·Nature Medicine

Abstract

Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure as identified by plasma suPAR ≥6 ng ml −1 , 85.9% ( n = 510) of whom were receiving dexamethasone. At day 28, the adjusted proportional odds of having a worse clinical status (assessed by the 11-point World Health Organization Clinical Progression Scale (WHO-CPS)) with anakinra, as compared to placebo, was 0.36 (95% confidence interval 0.26–0.50). The median WHO-CPS decrease on day 28 from baseline in the placebo and anakinra groups was 3 and 4 points, respectively (odds ratio (OR) = 0.40, P < 0.0001); the respective median decrease of Sequential Organ Failure Assessment (SOFA) score on day 7 from baseline was 0 and 1 points (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01499-z

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 536

Metadata

Authors
Kyriazopoulou, E., Poulakou, G., Milionis, H., Metallidis, S., Adamis, G., Tsiakos, K., Fragkou, A., Rapti, A., Damoulari, C., Fantoni, M., Kalomenidis, I., Chrysos, G., Angheben, A., Kainis, I., Alexiou, Z., Castelli, F., Serino, F. S., Tsilika, M., Bakakos, P., Nicastri, E., Tzavara, V., Kostis, E., Dagna, L., Koufargyris, P., Dimakou, K., Savvanis, S., Tzatzagou, G., Chini, M., Cavalli, G., Bassetti, M., Katrini, K., Kotsis, V., Tsoukalas, G., Selmi, C., Bliziotis, I., Samarkos, M., Doumas, M., Ktena, S., Masgala, A., Papanikolaou, I., Kosmidou, M., Myrodia, D.-M., Argyraki, A., Cardellino, C. S., Koliakou, K., Katsigianni, E.-I., Rapti, V., Giannitsioti, E., Cingolani, A., Micha, S., Akinosoglou, K., Liatsis-Douvitsas, O., Symbardi, S., Gatselis, N., Mouktaroudi, M., Ippolito, G., Florou, E., Kotsaki, A., Netea, M. G., Eugen-Olsen, J., Kyprianou, M., Panagopoulos, P., Dalekos, G. N., & Giamarellos-Bourboulis, E. J.
Venue
Nature Medicine
Published
2021-09-03
Volume
27
Issue
10
Pages
1752-1760
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3198379317
Cited by
536
References
28
FWCI
32.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. https://app.cochat.ai/papers/10.1038/s41591-021-01499-z
The paper
Kyriazopoulou, E., Poulakou, G., Milionis, H., Metallidis, S., Adamis, G., Tsiakos, K., Fragkou, A., Rapti, A., Damoulari, C., Fantoni, M., Kalomenidis, I., Chrysos, G., Angheben, A., Kainis, I., Alexiou, Z., Castelli, F., Serino, F. S., Tsilika, M., Bakakos, P., . . . Giamarellos-Bourboulis, E. J. (2021). Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01499-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.